News
Enara Bio raises $32.5 million Series B financing to advance first-in-class pipeline of TCR-based immunotherapies targeting novel Dark Antigens®
New investors Pfizer Ventures and M Ventures co-led the financing, with participation from all existing investors including RA Capital, Samsara BioCapital and SV Health Investors
Boehringer Ingelheim licenses multiple Dark Antigens® from Enara Bio to develop off-the-shelf immunotherapies for non-small cell lung cancer (NSCLC)
Licensed antigens are shared across major subsets of NSCLC and have confirmed presence on the surface of tumor cells, homogeneous expression within tumors, and strong immunogenicity
All News
Browse our full news archives
Publications
Scientific posters highlighting our Dark Antigens as novel immunotherapy targets for solid tumors
A short selection of the growing scientific literature that inspires us to shine a light on genomic dark matter
Upcoming & Recent Events
Discover the events that the Enara Bio team are attending